ZYMEWORKS INC. (ZYME) FY2026 Q2 P&L / Income Statement

ZYMEWORKS INC. (ZYME) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Partner. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Research and development collaborations

4,590,000 US dollars

Total operating expenses

46,770,000 US dollars

Loss from operations

negative 42,180,000 US dollars

Other income (expense), net (calculated)

negative 3,112,000 US dollars

(Loss) income before income taxes

negative 45,292,000 US dollars

Income tax recovery (expense)

negative 273,000 US dollars

Net (loss) income

negative 45,019,000 US dollars

Jazz - Development support payments

291,000 US dollars

Jazz - Drug supply for ongoing studies

791,000 US dollars

Jazz - Other drug supply

45,000 US dollars

Jazz - Royalties

1,589,000 US dollars

BeOne - Drug supply

1,664,000 US dollars

BeOne - Royalties

210,000 US dollars

Research and development

27,435,000 US dollars

General and administrative

19,335,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.